Sucampo Pharmaceuticals
| Company type | Public |
|---|---|
| Nasdaq: SCMP | |
| Industry | Pharmaceutical |
| Founded | 1996 |
| Headquarters | Bethesda, Maryland |
| Products | Amitiza |
| Website | sucampo |
Sucampo Pharmaceuticals, Inc. is a public, American biopharmaceutical company focused on medical applications of a class of ion channel modulators called prostones.[1][2]
Products
Sucampo has two marketed products, Amitiza and Rescula.[3] As of 2014[update], Takeda distributes this drug globally except for in Japan and China.[4]
Corporate governance
The company's chief financial officer, as of 2014, was Cary J. Claiborne.[5]
References
- ^ "SCMP—News and Analysis—Sucampo Pharmaceuticals, Inc". Seeking Alpha. Company description. Retrieved 1 January 2015.
- ^ Brewer, Jim (31 December 2014). "Sucampo Pharmaceuticals Hits New 12-Month High at $14.90 (SCMP)". WKRB News. WKRB.
- ^ Staff (5 December 2014). "Sucampo Pharmaceuticals (SCMP): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report".
- ^ House, Douglas W. (31 December 2014). "Canada accepts Sucampo's NDS for constipation med". Seeking Alpha.
- ^ Pearson, Nolan (30 December 2014). "Maxim Group Raises Sucampo Pharmaceuticals Price Target to $15.00". WKRB News. WKRB.
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |